North American Monoclonal Antibodies Market size is predicted to surpass USD 200 billion by 2028, according to a latest forecast report by Graphical Research.
Rising R&D by the pharmaceutical companies for the development of novel monoclonal antibodies will enhance the market growth. The monoclonal antibodies are becoming popular for the treatment of infectious diseases because of their recognition specificity towards bacterial exotoxins. Therefore, the increasing prevalence of infectious diseases such as ebola, COVID-19, HIV, dengue, and others will stimulate the market demand. As per FDA, more than 70 monoclonal antibodies are being approved for the use and more than 100 mAbs are under clinical development and trials.
As demand for mAbs grows, investment in technology to develop advanced antibodies is going to spike. Technology has allowed researchers to develop more complex and target-specific antibodies which can be used to treat various cancers and other autoimmune disorders. Thus, the monoclonal antibody is going to remain the dominant therapeutic modality for a wide range of ailments during the predicted timeframe.
The humanized monoclonal antibody segment will grow at 12.9% CAGR during the forecast period. The humanized mAbs is one of the popular modalities utilized for a wide range of therapeutic classes. These mAbs could efficiently control their effector functions while preventing the addition of immunogenicity. In addition, humanized mAbs have therapeutic applications for the treatment of ailments such as transplant rejection, psoriasis, cancer, infectious disease, asthma, and arthritis. Thus, the wide adoption of humanized monoclonal antibodies for various applications will augment the market revenue.
Browse detailed statistical insights from the report, “North America Monoclonal Antibodies Market Forecast 2028 By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By Type (Fully Human, Humanized, Chimeric), By End-use (Hospitals, Specialty Centers), Research Report, Country Outlook (U.S., Canada), COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @
The infectious disease segment will witness 13.7% CAGR through 2027. Substantial surge in coronavirus cases and an increasing number of mAb product approvals during the pandemic have contributed to the market growth. For instance, in May 2021, the U.S. FDA approved Sotrovimab for the treatment of mild-to-moderate COVID infection in patients. Thus, fast approval and growing product demand are going to augment the industry growth.
Specialty centers segment was valued at USD 22 billion revenue in 2021. High usage of monoclonal antibodies in specialty centers for the treatment of various infectious and chronic diseases is going to boost the market size. Moreover, a high preference for specialty clinics for consultation and treatment may result in high product demand. In addition, technological advancements at specialty centers facilities and supportive government policies will attribute to the market expansion.
U.S. monoclonal antibodies market will showcase around 12.7% growth rate from 2021 and 2028. The presence of major companies in the country is one of the major factors contribute to the market growth. Government is supporting manufacturing capacity expansion and many product approvals. Furthermore, increasing investment and rising government initiative to spread awareness about mAbs will further augment the market demand.
The monoclonal antibodies in North American market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2016 to 2027, for the following segments:
North America Market, By Type
- Fully Human
North America Market, By Application
- Autoimmune diseases
- Infectious diseases
North America Market, By End-use
- Specialty Centers
The above information has been provided for the following countries: